Community Pharmacy Programmes
Page last updated: 11 December 2015
Up to $1.26 billion in funding will be available under the Sixth Community Pharmacy Agreement (6CPA) for evidence-based, patient-focused professional pharmacy programmes and services. This will consist of:
- $613 million for the continuation of a number of programmes and services from 5CPA;
- $50 million for a new pharmacy trial programme; and
- up to $600 million for new and expanded community pharmacy programmes.
Under 6CPA, all programmes and services will be reviewed for clinical and cost‑effectiveness and the health benefits they offer to the community by an independent health technology assessment body, such as the Medical Services Advisory Committee (MSAC), to be determined by the Minister.
This process will ensure pharmacy programmes and services are assessed against the same standards of evidence as for other health professions. It supports a consistent approach to informing investment that delivers the greatest benefit to consumers, and will include existing programmes and services, as well as investment in a range of new programmes and services delivered through community pharmacy.
It is expected that the way programmes and services are assessed will differ, based on levels of existing evidence. Many services have a greater evidence base as they are well established, and some services are more recent. In addition, assessments will look prospectively at what information may be needed to inform recommendations, particularly for trial programmes which will be implemented under the 6CPA.
Pharmacy Trial Programme
Under 6CPA the Pharmacy Trial Programme will trial new and expanded community pharmacy programmes which seek to improve clinical outcomes for consumers and extend the role of pharmacists in the delivery of primary healthcare services through community pharmacy. The 6CPA notes particular priority will be given to rural and remote Australia, as well as particular population groups such as Aboriginal and Torres Strait Islander peoples.
In determining priority areas for the trials, extensive consultations will be undertaken with a range of stakeholders, individuals and peak groups, as well as identifying evidence to support proposed trials. These consultations will focus on trials that also seek to improve access to pharmacy and pharmacist services, and measurably demonstrating this.
For the first year of 6CPA the programme administration will continue to be delivered by the Pharmacy Guild of Australia. However, during this year the market will be tested to see if this role can be delivered in a more innovative, efficient, and cost effective manner.
Programme Administration services and resources are currently available from the Pharmacy Guild of Australia.